Skip to main content
. Author manuscript; available in PMC: 2023 Feb 1.
Published in final edited form as: Life Sci. 2021 Dec 23;290:120247. doi: 10.1016/j.lfs.2021.120247

Figure 4.

Figure 4.

Immunohistochemistry of LV tissues for cardiomyocytes and fibroblasts. Following OVX and/or 17β-estradiol treatment, LV tissue preparation and sectioning were carried out as described in the Methods section. A) Diagram of LV sectioning and imaging locations in each section. B) Control images of LV sections processed though IHC procedures with only fluorescent secondary antibodies, AlexaFluor488 goat anti-rabbit IgG (left) and AlexaFluor594 goat anti-mouse IgG (right), but without primary antibodies. C) Background-subtracted IHC images for vimentin (Vim), troponin T (TnT), nuclei (DAPI) and merged of these. D) Total surface area of cardiomyocytes. E) Total surface area of cardiac fibroblasts. F) Emission spectra and peaks of equal concentration (1:200 dilution) AlexaFluor 488 goat anti-rabbit IgG (green) and AlexaFluor 594 goat anti-mouse IgG (red). G) Relative total surface areas between fibroblasts and cardiomyocytes in the same LV sections (TSACF/CM). See text for description. Data are means ± SD from 6 sampling windows (depicted in A) in each LV section, n = 3 animals from each treatment condition, ns, non-significant; *, p < 0.05; **, p < 0.01; ****, p < 0.0001; scale bars, 200 μm.